Wednesday, October 14, 2026

CBOE Over 28% Up In The Last 21 Sessions

ViaNews Editorial Team

October 3, 2023

CBOE Over 28% Up In The Last 21 Sessions

(VIANEWS) - CBOE (VIX) has been up by 28.58% for the last 21 sessions. At 04:08 EST on Tuesday, 3 October, CBOE (VIX) is $17.77.

About CBOE's yearly highs and lows, it's 14.42% up from its 52-week low and 49.3% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was a negative 1.87%, a positive 1.78%, and a positive 4.24%, respectively.

CBOE's highest amplitude of average volatility was 2.64% (last week), 4.46% (last month), and 4.24% (last quarter), respectively.

News about

  • According to MarketWatch on Monday, 2 October, "The Renaissance IPO ETF IPO has gained 30% in the year to date, while the S&P 500 SPX has gained 11.7%."
  • According to MarketWatch on Monday, 2 October, "Rivian's stock, which had climbed 17.9% over the past five sessions, has run up 45.7% over the past three months, while the S&P 500 index SPX has lost 3.7%."
  • According to MarketWatch on Sunday, 1 October, "The Dow Jones Industrial Average DJIA posted a 3.5% decline in September, its biggest monthly loss since February, the S&P 500 index SPX fell 4.8% and the Nasdaq Composite Index COMP shed 5.8% for the month."
  • According to MarketWatch on Monday, 2 October, "But...theprice level of the S&P 500 is approaching an area of attractive risk/reward," wrote Lee in a note.", "On Friday, the Dow Jones Industrial Average DJIA fell 159 points, or 0.47%, to 33508, the S&P 500 SPX declined 12 points, or 0.27%, to 4288, and the Nasdaq Composite COMP gained 18 points, or 0.14%, to 13219."

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com